New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:47 EDTMYGN, LHMyriad Genetics participation pacts to be terminated by NJ Horizon Blue Cross
Horizon Blue Cross Blue Shield of New Jersey, an independent licensee of the Blue Cross and Blue Shield Association, announced yesterday that it is terminating its participation agreements with Myriad Genetics (MYGN), effective June 15 for patients enrolled in Horizon BCBSNJ managed care plans and effective July 3 for patients enrolled in Horizon BCBSNJ PPO and Indemnity plans. Following the terminations of Myriad Genetics, LabCorp (LH) will be the only participating clinical laboratory to provide BRCA-specific genetic testing for Horizon BCBSNJ patients, the insurer noted. Reference Link
News For MYGN;LH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
10:52 EDTMYGN, LHLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
March 27, 2015
10:03 EDTLHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:12 EDTLHLabCorp initiated with an Outperform at JMP Securities
Subscribe for More Information
March 26, 2015
10:04 EDTMYGNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:07 EDTMYGNMyriad Genetics downgraded to Sell from Neutral at Goldman
Subscribe for More Information
March 25, 2015
08:53 EDTLHLabCorp has a conference call hosted by JPMorgan
Subscribe for More Information
March 24, 2015
08:30 EDTLHLabCorp shares should be bought at current levels, says Maxim
Subscribe for More Information
07:46 EDTLHLabCorp price target raised to $160 from $141 at Maxim
Subscribe for More Information
March 20, 2015
07:41 EDTMYGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
05:17 EDTMYGNMyriad EMPATHY-P clinical study results to be highlighted at annual congress
Myriad Genetics announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods, which were then compared to the Prolaris test results. The EMPATHY-P data showed, overall, that the Prolaris test found 42% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use